Skip to content

The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

Multiple Sclerosis Biosimilars Landscape

Natalizumab was approved in 2004 for the treatment of patients with relapsing forms of multiple sclerosis (MS) and in 2008 to treat moderate-to-severe-Crohn’s disease. In July 2022 the Food and drug Administration (FDA) accepted a Biologics License Application (BLA) for a proposed biosimilar to natalizumab being developed to treat relapsing forms of MS including clinicallyContinue reading “Multiple Sclerosis Biosimilars Landscape”

Rheumatology Biosimilars Landscape

Adalimumab was approved by Food and Drug Administration (FDA) in 2002 for the treatment of rheumatoid arthritis and, in subsequent years, gained approval for the treatment of additional conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, inflammatory bowel disease, and uveitis. In 2023, several adalimumab biosimilars from different manufacturers are anticipated to enterContinue reading “Rheumatology Biosimilars Landscape”

New and upcoming biosimilar launches

Humira™ biosimilar landscape overview

Prescribing Biosimilar and Interchangeable Biosimilar Products

Curriculum Materials for Health Care Degree Programs – Biosimilars

Overview of Biosimilar Products

A bio-what? Medical companions’ perceptions towards biosimilars and information needs in rheumatology

Biosimilars Are Here: A Hospital Pharmacist’s Guide to Educating Health Care Professionals on Biosimilars